Skip to main content
OpenTrials
Completed

NCT Number: NCT02876445

Caregiver Burden in Huntington's Disease

Huntington's disease (HD) is a rare inherited neurodegenerative disorder, progressing between 15 and 20 years and affecting one person out of 10.000. In France, it concerns some 6.000 patients symptomatic and 12 000 asymptomatic carriers.

Few extensive researches have been conducted on the progression of the disease, which is defined in the literature in 5 stages in a functional approach.

Therapeutically, no cure for HD is currently validated but only symptomatic treatments. There's various treatment options: medicated, humans (physiotherapy, speech therapist, occupational therapist, ..).

Although these treatment options do not prevent the progression of the disease, their combination associated with a stimulating environment may slow the decline of physical, intellectual and psychic abilities of patients.

In social terms, patients with HD require sustained support, especially in cases of family isolation.

The behavioural, gaiting and eating disorder as well as the communications difficulties make it difficult support daily for the entourage. The caregivers are sometimes dealing with untenable situations. Home care services, which are crucial to alleviating dependency, relieve family caregivers but are for the most severe patient.

Moreover, the justified placement decision in an institution generates a feeling of guilt for the family.

The caregiver is the person who brings non-professional assistance , partly or wholly , to a dependent member of his entourage , for the activities of daily living. This regular care may be provided permanently or not. It can take many forms, such as , care , nursing , support to education and social life , administrative procedures , psychological support .

Caregivers have their lives profoundly reshaped. They are often forced to give up some of their habits , give up their future plans , change their relationships. The commitment of caregivers with patients with Huntington's disease actually sounds on their mental and physical health, as well as their social and professional life

Very few studies have been conducted to measure the difficulties and implications of these caregivers.

Completed

Looking for future studies?

Notify Me

Key information

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age ≥ 18
  • Primary caregiver of patient with Huntington's disease
  • Non- institutionalized Patient
  • stage 1-4 (no institutionalization within 2 years)
  • written consent

Exclusion criteria

  • Not agreement

Treatment and study plan

ZARIT Burden Interview

Other

ZARIT Burden Interview completed Day 0 and 1 year

Primary outcomes

  1. Evaluation with ZARIT's scale of the burden level of the management of a patient with Huntington's disease by his caregiver

    Time frame: 1 year

Secondary outcomes

  1. Measuring social impact of the disease using the under score of ZARIT's scale for the patient and the caregiver

    Time frame: 1 year

  2. Measuring professional impact of of the disease using the under score of ZARIT's scale for the patient and the caregiver

    Time frame: 1 year

Sponsors and collaborators

Lead sponsor

Assistance Publique - Hôpitaux de Paris

Other

Registry information

Official study title

Assessment Study on Family Burden in Overall Care of Patient With Huntington Disease

Acronym: PHRI-HD

Important dates

Study start
2011
Primary completion
2016
Study completion
2016
First posted
Aug 23, 2016
Registry last updated
Aug 23, 2016

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.